Nonalcoholic fatty liver disease in subjects with adrenal incidentaloma

European Journal of Clinical Investigation

Volumn 42, Issue 11, 2012, Pages 1165-1172

  Papanastasiou, Labrini ^a   Pappa, Theodora ^a   Samara, Christianna ^b   Apostolopoulou, Glyceria ^b   Tsiavos, Vaios ^a   Markou, Athina ^a   Alexandraki, Krystallenia ^a   Piaditis, George ^a   Chrousos, George ^a   Kaltsas, Gregory ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b G GENNIMATAS GENERAL HOSPITAL   (Greece)

Author keywords

Adrenal incidentaloma; Insulin resistance; Metabolic syndrome; Nonalcoholic fatty liver disease

Indexed keywords

ALDOSTERONE; HYDROCORTISONE;

ADRENAL INCIDENTALOMA; ADULT; ARTICLE; BODY MASS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FATTY LIVER; FEMALE; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; ORAL GLUCOSE TOLERANCE TEST; PHEOCHROMOCYTOMA; PREVALENCE; PRIORITY JOURNAL; SPLEEN; WAIST HIP RATIO;

ADRENAL GLAND NEOPLASMS; ALDOSTERONE; ANTHROPOMETRY; BODY MASS INDEX; CASE-CONTROL STUDIES; FATTY LIVER; FEMALE; HUMANS; HYDROCORTISONE; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PREVALENCE; REGRESSION ANALYSIS; TOMOGRAPHY, X-RAY COMPUTED; WAIST-HIP RATIO;

EID: 84867744683     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2012.02707.x     Document Type: Article

References (40)

1. Young WF Jr. Clinical practice. The incidentally discovered adrenal mass. N Engl J Med 2007;356:601-10.
2. Bovio S, Cataldi A, Reimondo G, Sperone P, Novello S, Berruti A et al. Prevalence of adrenal incidentaloma in a contemporary computerized tomography series. J Endocrinol Invest 2006;29:298-302.
3. Zeiger MA, Siegelman SS, Hamrahian AH. Medical and surgical evaluation and treatment of adrenal incidentalomas. J Clin Endocrinol Metab 2011;96:2004-15.
4. Mansmann G, Lau J, Balk E, Rothberg M, Miyachi Y, Bornstein SR. The clinically inapparent adrenal mass: update in diagnosis and management. Endocr Rev 2004;25:309-40.
5. Terzolo M, Stigliano A, Chiodini I, Loli P, Furlani L, Arnaldi G et al. Italian Association of Clinical Endocrinologists AME position statement on adrenal incidentaloma. Eur J Endocrinol 2011;164:851-70.
6. Reincke M, Fassnacht M, Vath S, Mora P, Allolio B. Adrenal incidentalomas: a manifestation of the metabolic syndrome? Endocr Res 1996;22:757-61.
7. Fernandez-Real JM, Engel WR, Simo R, Salinas I, Webb SM. Study of glucose tolerance in consecutive patients harbouring incidental adrenal tumours. Study Group of Incidental Adrenal Adenoma. Clin Endocrinol (Oxf) 1998;49:53-61.
8. Rossi R, Tauchmanova L, Luciano A, Di Martino M, Battista C, Del Viscovo L et al. Subclinical Cushing's syndrome in patients with adrenal incidentaloma: clinical and biochemical features. J Clin Endocrinol Metab 2000;85:1440-8.
9. Terzolo M, Pia A, Ali A, Osella G, Reimondo G, Bovio S et al. Adrenal incidentaloma: a new cause of the metabolic syndrome? J Clin Endocrinol Metab 2002;87:998-1003.
10. Peppa M, Boutati E, Koliaki C, Papaefstathiou N, Garoflos E, Economopoulos T et al. Insulin resistance and metabolic syndrome in patients with nonfunctioning adrenal incidentalomas: a cause-effect relationship? Metabolism 2010;59:1435-41.
11. Piaditis GP, Kaltsas GA, Androulakis II, Gouli A, Makras P, Papadogias D et al. High prevalence of autonomous cortisol and aldosterone secretion from adrenal adenomas. Clin Endocrinol (Oxf) 2009;71:772-8.
12. Androulakis II, Kaltsas G, Piaditis G, Grossman AB. The clinical significance of adrenal incidentalomas. Eur J Clin Invest 2011;41:552-60.
13. Utzschneider KM, Kahn SE. Review: the role of insulin resistance in nonalcoholic fatty liver disease. J Clin Endocrinol Metab 2006;91:4753-61.
14. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002;346:1221-31.
15. Kim CH, Younossi ZM. Nonalcoholic fatty liver disease: a manifestation of the metabolic syndrome. Cleve Clin J Med 2008;75:721-8.
16. Ghouri N, Preiss D, Sattar N. Liver enzymes, nonalcoholic fatty liver disease, and incident cardiovascular disease: a narrative review and clinical perspective of prospective data. Hepatology 2010;52:1156-61.
17. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006;43:S99-112.
18. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999;116:1413-9.
19. Brunt EM, Kleiner DE, Wilson LA, Belt P, Neuschwander-Tetri BA. Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology 2011;53:810-20.
20. Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002;123:745-50.
21. Piekarski J, Goldberg HI, Royal SA, Axel L, Moss AA. Difference between liver and spleen CT numbers in the normal adult: its usefulness in predicting the presence of diffuse liver disease. Radiology 1980;137:727-9.
22. Duman DG, Celikel C, Tuney D, Imeryuz N, Avsar E, Tozun N. Computed tomography in nonalcoholic fatty liver disease: a useful tool for hepatosteatosis assessment? Dig Dis Sci 2006;51:346-51.
23. Jacobs JE, Birnbaum BA, Shapiro MA, Langlotz CP, Slosman F, Rubesin SE et al. Diagnostic criteria for fatty infiltration of the liver on contrast-enhanced helical CT. AJR Am J Roentgenol 1998;171:659-64.
24. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-9.
25. Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000;85:2402-10.
26. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999;22:1462-70.
27. Nieman LK, Biller BM, Findling JW, Newell-Price J, Savage MO, Stewart PM et al. The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2008;93:1526-40.
28. Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser M et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2008;93:3266-81.
29. Tauchmanova L, Rossi R, Biondi B, Pulcrano M, Nuzzo V, Palmieri EA et al. Patients with subclinical Cushing's syndrome due to adrenal adenoma have increased cardiovascular risk. J Clin Endocrinol Metab 2002;87:4872-8.
30. Wagnerova H, Dudasova D, Lazurova I. Hormonal and metabolic evaluation of adrenal incidentalomas. Neoplasma 2009;56:521-5.
31. Rockall AG, Sohaib SA, Evans D, Kaltsas G, Isidori AM, Monson JP et al. Hepatic steatosis in Cushing's syndrome: a radiological assessment using computed tomography. Eur J Endocrinol 2003;149:543-8.
32. Garrapa GG, Pantanetti P, Arnaldi G, Mantero F, Faloia E. Body composition and metabolic features in women with adrenal incidentaloma or Cushing's syndrome. J Clin Endocrinol Metab 2001;86:5301-6.
33. Di Dalmazi G, Vicennati V, Rinaldi E, Morselli-Labate AM, Giampalma E, Mosconi C et al. Progressively increased patterns of subclinical cortisol hypersecretion in adrenal incidentalomas differently predict major metabolic and cardiovascular outcomes: a large cross-sectional study. Eur J Endocrinol 2012;166:669-77.
34. Kral JG, Schaffner F, Pierson RN Jr, Wang J. Body fat topography as an independent predictor of fatty liver. Metabolism 1993;42:548-51.
35. Park BJ, Kim YJ, Kim DH, Kim W, Jung YJ, Yoon JH et al. Visceral adipose tissue area is an independent risk factor for hepatic steatosis. J Gastroenterol Hepatol 2008;23:900-7.
36. Smith BW, Adams LA. Nonalcoholic fatty liver disease and diabetes mellitus: pathogenesis and treatment. Nat Rev Endocrinol 2011;7:456-65.
37. Limanond P, Raman SS, Lassman C, Sayre J, Ghobrial RM, Busuttil RW et al. Macrovesicular hepatic steatosis in living related liver donors: correlation between CT and histologic findings. Radiology 2004;230:276-80.
38. Szczepaniak LS, Nurenberg P, Leonard D, Browning JD, Reingold JS, Grundy S et al. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab 2005;288:E462-8.
39. Fabbrini E, Magkos F, Mohammed BS, Pietka T, Abumrad NA, Patterson BW et al. Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. Proc Natl Acad Sci USA 2009;106:15430-5.
40. Assy N. Nutritional recommendations for patients with non-alcoholic fatty liver diseases. World J Gastroenterol 2011;17:3375-6.